Corcept Therapeutics (CORT) closed at $81.93 on Nov 3, 2026, up 1.8% on the day. The stock is down 32.9% over the past month, down 26.0% over three months, up 135.4% year to date and up 10.5% over the past year (since Nov 3, 2025). It trades 35.2% below its 52-week high of $126.38 and 185.9% above its 52-week low of $28.66. The close sits below its 50-day moving average ($110.31) and above its 200-day moving average ($75.23).
Over its last 8 reports the stock moved an average of 7.9% on the first trading day after earnings, beating the options-implied move in 2 of 8.
CORT options were pricing 91% at-the-money implied volatility on Oct 30, 2026, an IV rank of 51 over the past year.
Over the last 8 reports, CORT moved an average of 7.9% on the first trading day after earnings. The move beat the options-implied move in 2 of 8 reports.
Yes — the Nov 3, 2026 close of $81.93 is 8.9% above the 200-day average of $75.23.
CORT closed 35.2% below its 52-week high of $126.38.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
